Biotech Values

[biomaven0]

FGEN
>> where is that quote from? AZN CC on 2/4?

Yes. There were a bunch of analyst questions relating to the roxa program in China. Bottom line is that it's a rolling submission starting this year, but they can't predict any timelines because of lack of precedent.

There are very significant China milestones from AZN, so clearly they think there is considerable opportunity.

Peter